Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2021
Message from the CEO IBT is conducting a phase III-study (“The Connection Study”) which is…
Month: May 2021
Immunicum AB (publ) Interim Report January – March 2021
Press Release 4 May 2021 Immunicum AB (publ) Interim Report January – March 2021 JANUARY…
Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar
Press Release Nicox’s Licensee Bausch + Lomb Launches VYZULTA®(latanoprostene bunod ophthalmic solution), 0.024% in Taiwan…
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
– EDELWEISS 3 trial of Yselty® expected to report topline data as planned in Q4:21-…
Innate Pharma Announces Conference Call and Webcast for 2021 First Quarter Business Update
MARSEILLE, France, May 04, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH –…
NovoBiome launched to revolutionize treatment of liver diseases by targeting the microbiome-gut-liver axis
NovoBiome launched to revolutionize treatment of liver diseases by targeting the microbiome-gut-liver axis First biotech…
Innate Pharma Announces Conference Call and Webcast for 2021 First Quarter Business Update
Marseille, France, May 04, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH –…
Acacia Pharma Announces Early Repayment of Loan Facility from Hercules Technology Growth Capital and Reduction in Debt Service Obligations
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION Acacia Pharma Announces Early Repayment of…
Syneos Health Announces Pricing of Secondary Offering of Common Stock
MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company”…
Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Convertible Bonds due 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL…
Teligent, Inc. Announces 2020 Year-End Earnings Report and Provides Business Update
– Significantly strengthened balance sheet and cash position – Continued FDA Warning Letter remediation efforts…
New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
Vaxart oral vaccine induced higher CD8+ T-Cell responses than those seen with Moderna or Pfizer vaccines in…
Syneos Health Announces Secondary Offering of Common Stock
MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company”…
Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update
MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused…
PLx Pharma Inc. to Discuss 2021 First Quarter Financial Results on May 14, 2021 Conference Call and Provide Business Update
SPARTA, N.J., May 03, 2021 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or…
ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. WESTMINSTER, Colo., May 03,…
Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium
Presentation will highlight efficacy and safety data from the DERMIS-1 and DERMIS-2 pivotal Phase 3…
Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitis
Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans…
Tower One Announces Filing of its Q4 and Year 2020 Annual Report
VANCOUVER, British Columbia, May 03, 2021 (GLOBE NEWSWIRE) — TOWER ONE WIRELESS CORP. (CSE: TO)…
Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives
Highlights: Revenue of $173.1 million increases 12% sequentially GAAP earnings per share of ($0.52), adjusted…